Fluorescent Excitation Analysis for In Vitro Tests

Sybil J. Swann, Leon Kaufman, David C. Price, Pierre Guesry*, Shelly Orloff, Carol J. Wilson†, and John P. Huberty

University of California, San Francisco, San Francisco, California

Use of fluorescent excitation analysis for in vitro tests eliminates patient exposure to radiation. Tests already developed measure extracellular fluid volume, red cell volume, and glomerular filtration rates. These compare favorably with alternate techniques.

The applications and usefulness of fluorescent excitation analysis (FEA) in performing some in vitro tests currently using radioactive labels or chemical analysis of stable elements are outlined. FEA is fast, accurate, and cost effective and avoids exposing the patient or attending personnel to radiation. This can be extremely important when studying children, pregnant women, normal volunteers, and when performing serial studies on the same subject.

Technique

When an in vitro test is performed using a radioactive tracer, the patient receives a certain amount of radiation associated with that tracer. Attending personnel are also exposed. Since all counting is performed outside the patient, e.g., in a well counter, it would be ideal if the tracer could be rendered "radioactive" just during counting. FEA is a technique that achieves this in a convenient way.

When an element is bombarded by a beam of gamma ray or x-ray photons with an energy higher than the binding energy (BE) of the K-shell electrons in an atom, ejection of these electrons occurs, thereby generating a vacancy in the K-shell. This vacancy is subsequently filled by either an L-shell or M-shell electron. In this process the atom emits photons of two different and unique energies, Kα and Kβ, which are called the characteristic radiations and are unique to each element (Fig. 1). The same process can occur in other electron shells, producing lower energy characteristic x-rays with lower yield. The process of exciting stable elements to emit characteristic radiations is termed fluorescent excitation (1).

The exciting photons can also undergo Compton scattering, producing secondary photons of an energy lower than that of the exciting (original) beam, with the exact value of that energy depending on the scattering angle. Detectors with very precise energy resolution are needed to separate the fluorescent radiations from each other and from all other radiations reaching the detector (mainly Compton scattering). Thus, lithium-compensated silicon detectors [Si(Li)] are commonly used since they achieve energy resolutions in the order of 400 eV FWHM for the x-rays of iodine. This excellent energy resolution is due to the direct and efficient manner in which the energy of incoming x-rays is transferred into charge (a 30-keV x-ray produces a signal consisting of 10,000 electrons that are fully collected). For NaI, on the other hand, the incoming photon energy is transferred first to one electron, which then produces secondary ionization that generates light. Only a fraction of this light reaches the photomultiplier tube, at which point charge is once again produced (Fig. 2). For a 30-keV x-ray, only 10–30 electrons are produced at the cathode of the tube. Energy resolution

*Present address: Hospital des Enfants Malades, Paris, France.
†Present address: Baylor College of Medicine, Houston, Texas.
For reprints contact: Sybil J. Swann, Dept. of Radiology, Nuclear Medicine Section, University of California Medical Center at San Francisco, San Francisco, Calif. 94143.
in Si(Li) far surpasses that of NaI and makes the former critically valuable in practical FEA systems.

**Equipment**

Figure 3 illustrates the present automated system, which has been developed in collaboration with the Lawrence Livermore Laboratory (Radiochemistry Division, Livermore, Calif.), the KeVex Corp. (Analytical Products Division, Burlingame, Calif.), and Ino-Tech, Inc. (Madison, Wis.). It consists of an optimized Si(Li) detector, an automated special sample changer, and a programmable pulse height analyzer. An encapsulated $^{241}$Am (60 keV) source is used for iodine and cesium FEA, and $^{109}$Cd (22 keV) is used for bromine FEA. The sample changer holds 48 2-cc vials and has a mixing mode prior to analysis.

Figure 4 shows schematically the geometry in which the sample is analyzed. Source and detector are collimated at 90 deg to each other, and the sample is placed in the sensitive volume defined by the intersection of the collimators. A typical spectrum for an iodine-containing sample is shown in Fig. 5. Tracer concentration in the sample is calculated using the formula:

\[
\text{Tracer Concentration} = \frac{\text{Net Count}}{\text{Background Count}} \times \text{Calibration Factor}
\]
1.0 and 40-min samples were counted using FEA and the RCV was calculated using the following formula: 
RCV = \frac{\text{Injectate weight} \times (\text{Cs conc in injectate}) \times (\text{fractional hematocrit})}{\text{(specific gravity of blood)} \times (\text{Cs conc in blood sample})}.

Table 2 shows the comparison of the radioactive ($^{51}$Cr) versus the nonradioactive techniques (CsCl$_2$). As can be seen, there was excellent agreement between the two.

A reliable and simple determination of GFR would aid in the clinical evaluation of renal disease and its progress during therapy. Inulin clearance thus far has been the most reliable method for measurement of GFR. However, this technique requires 4-8 hr of technologist time to set up and to analyze samples for one patient.

The use of radioactive $^{125}$I-iothalamate is also accepted for GFR determinations. Again, this technique is expensive, and repeated determinations are limited due to radiation exposure to the patient. Figures 6 and 7 show GFR results obtained using Conray-60 (stable meglumine iothalamate) and FEA that compare with clinically accepted clearances (4). The Conray-60 technique is performed much the same as the

---

**Results**

The bromide ECFV has been measured in the past either with $^{82}$Br or by chemical assay (Conway’s microdiffusion technique) of stable bromine (2). Radioactive labels present obvious disadvantages both in isotope decay (i.e., limited shelf-life) and in exposure to the subject. Chemical analysis of bromine is performed by a trained technologist and is limited to determinations of only two patient studies per day. Using stable bromine and FEA all four samples needed for a single patient determination (injected standard, preinjection plasma, and 3- and 4-hr plasma samples) can be analyzed in 5 min (Table 1).

RCV determinations were done in a series of patients using both $^{51}$Cr and stable cesium chloride (CsCl$_2$) to label autologous red cells (3). The labeling procedure was facilitated by the addition of nystatin. The procedure followed the conventional technique of radioactive labeling of red cells with the exception of extra saline washes after the incubation period. The routine

---

**TABLE 1. System Accuracy for Bromine (April 1975)**

<table>
<thead>
<tr>
<th>Count time</th>
<th>Concentration range (mEq/liter)</th>
<th>Reproducibility (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 sec</td>
<td>500 to 75</td>
<td>$\sigma \leq 1$</td>
</tr>
<tr>
<td>1 min</td>
<td>$\sim 9$</td>
<td>$\sigma \approx 1.2$</td>
</tr>
<tr>
<td>2 min</td>
<td>$\sim 0.5$</td>
<td>$\sigma \approx 4$</td>
</tr>
<tr>
<td>15 min</td>
<td>$\sim 0.075$</td>
<td>$\sigma = 5$</td>
</tr>
</tbody>
</table>

Clinical range: Injectate $= 300$ mEq/liter; plasma levels $= 1-2$ mEq/liter.

Chemical analysis: $\sigma = 2.6\%$, eight samples/8-hr day.

**TABLE 2. Human Red Cell Volumes**

<table>
<thead>
<tr>
<th>Tracer</th>
<th>Volume (liter)</th>
<th>Cs Volume (liter)</th>
<th>Difference (%)</th>
<th>10 min</th>
<th>40 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{51}$Cr</td>
<td>$^{51}$Cr</td>
<td>$^{51}$Cr</td>
<td>$^{51}$Cr</td>
<td>$^{51}$Cr</td>
<td>$^{51}$Cr</td>
</tr>
<tr>
<td>1</td>
<td>2.30</td>
<td>2.44</td>
<td>6.1</td>
<td>2.24</td>
<td>2.15</td>
</tr>
<tr>
<td>2</td>
<td>1.69</td>
<td>1.64</td>
<td>-3.0</td>
<td>1.71</td>
<td>1.73</td>
</tr>
<tr>
<td>3</td>
<td>0.75</td>
<td>0.71</td>
<td>-5.3</td>
<td>0.76</td>
<td>0.78</td>
</tr>
<tr>
<td>4</td>
<td>1.39</td>
<td>1.45</td>
<td>4.3</td>
<td>1.41</td>
<td>1.46</td>
</tr>
<tr>
<td>5</td>
<td>1.10</td>
<td>1.16</td>
<td>5.5</td>
<td>1.00</td>
<td>1.33</td>
</tr>
<tr>
<td>6</td>
<td>1.35</td>
<td>1.38</td>
<td>2.2</td>
<td>1.35</td>
<td>1.35</td>
</tr>
<tr>
<td>7</td>
<td>1.01</td>
<td>0.98</td>
<td>-3.0</td>
<td>1.01</td>
<td>1.00</td>
</tr>
<tr>
<td>8</td>
<td>3.46</td>
<td>3.26</td>
<td>-5.8</td>
<td>3.56</td>
<td>3.41</td>
</tr>
<tr>
<td>9</td>
<td>2.29</td>
<td>2.22</td>
<td>-3.1</td>
<td>2.22</td>
<td>2.24</td>
</tr>
<tr>
<td>10</td>
<td>1.24</td>
<td>1.29</td>
<td>4.0</td>
<td>1.28</td>
<td>1.36</td>
</tr>
<tr>
<td>11</td>
<td>2.91</td>
<td>2.93</td>
<td>0.7</td>
<td>2.99</td>
<td>2.98</td>
</tr>
<tr>
<td>Mean</td>
<td>2.0</td>
<td>2.0</td>
<td>0.2</td>
<td>1.95</td>
<td>1.95</td>
</tr>
<tr>
<td>s.d.</td>
<td>4.4</td>
<td>4.4</td>
<td>7.5</td>
<td>7.5</td>
<td>7.5</td>
</tr>
<tr>
<td>$p$</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
<td></td>
<td>&lt;.001</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

---

**FIG. 5.** Typical spectrum from iodine-containing sample excited by 241Am.
126 I-iothalamate, with the advantages of low cost per study and no radiation exposure to the patient. As can be seen, only four blood samples are necessary, a preinjection, and 2-, 3-, and 4-hr after injection. This replaces the more involved techniques that require eight blood samples and two-exponential analysis.

Conclusion

The results thus far have demonstrated that FEA of nonradioactive tracer elements can be applied routinely to many in vitro tests. The advantages of this technique over radioactive or chemical analysis have been discussed and include increased accuracy, low cost, and, most importantly, the absence of radiation exposure to the patient. This is of particular importance in making these studies available to broad population groups.

Acknowledgments

These investigations are supported by USPHS Grant GM-21017 and NIGMS Career Development Award GM-70598. The authors wish to acknowledge the collaboration of the KeVex Corp. and Ino-Tech, Inc.

References